We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+13.4%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.23B
AUM Growth
-$147M
(-6.2%)
Cap. Flow
-$391M
Cap. Flow
% of AUM
-17.54%
Top 10 Holdings %
Top 10 Hldgs %
45.21%
Holding
76
New
10
Increased
18
Reduced
33
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$34.9M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$31.3M |
| 3 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$29M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$22.3M |
| 5 |
Medtronic
MDT
|
+$21.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$64.7M |
| 2 |
Amgen
AMGN
|
+$44.1M |
| 3 |
Viatris
VTRS
|
+$34.4M |
| 4 |
AbbVie
ABBV
|
+$25.7M |
| 5 |
CELG
Celgene Corp
CELG
|
+$24.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Universal Health Services
UHS
$10.1B
| $6.86M | 0.31% |
+61,666
| New | +$6.48M |
|
52
Inogen
INGN
$174M
| $6.49M | 0.29% |
206,734
-44,866
| -18% | -$1.09M |
|
53
Novartis
NVS
$304B
| $5.88M | 0.26% |
70,866
+24,440
| +53% | +$2.03M |
|
|
ALDR
54
DELISTED
Alder Biopharmaceuticals
ALDR
| $3.03M | 0.14% |
104,300
+15,000
| +17% | +$269K |
|
|
RNA
55
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
| $2.09M | 0.09% |
111,432
+17,248
| +18% | +$245K |
|
|
ZSPH
56
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $1.99M | 0.09% |
+47,895
| New | +$1.89M |
|
57
Accuray
ARAY
$29M
| $1.71M | 0.08% |
+226,300
| New | +$1.6M |
|
|
ADXS
58
DELISTED
Advaxis Inc
ADXS
| $1.69M | 0.08% |
+14,057
| New | +$790K |
|
59
Tandem Diabetes Care
TNDM
$1.22B
| $1.67M | 0.07% |
13,142
+3,000
| +30% | +$416K |
|
60
uniQure
QURE
$2.52B
| $1.39M | 0.06% |
+94,101
| New | +$1.15M |
|
|
WX
61
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
| $1.36M | 0.06% |
40,373
+21,500
| +114% | +$759K |
|
|
CARM
62
DELISTED
Carisma Therapeutics
CARM
| $1.34M | 0.06% |
5,624
| – | – |
|
|
IMDZ
63
DELISTED
Immune Design Corp.
IMDZ
| $652K | 0.03% |
21,181
-73,819
| -78% | -$2.05M |
|
64
Bausch Health
BHC
$1.69B
| $258K | 0.01% |
1,800
-93,600
| -98% | -$12.6M |
|
|
65
AbbVie
ABBV
$465B
| – | – |
-444,107
| Closed | -$25.7M |
|
66
Boston Scientific
BSX
$68.5B
| – | – |
-1,047,166
| Closed | -$12.4M |
|
67
Cigna
CI
$79.6B
| – | – |
-103,164
| Closed | -$9.36M |
|
68
Insmed
INSM
$22.6B
| – | – |
-1,625,323
| Closed | -$21.2M |
|
69
Innoviva
INVA
$1.61B
| – | – |
-971,438
| Closed | -$16.6M |
|
70
ProQR Therapeutics
PRQR
$248M
| – | – |
-70,000
| Closed | -$1.2M |
|
|
CMRX
71
DELISTED
Chimerix, Inc.
CMRX
| – | – |
-842,149
| Closed | -$23.3M |
|
|
IMGN
72
DELISTED
Immunogen Inc
IMGN
| – | – |
-2,269,597
| Closed | -$24M |
|
|
ANTH
73
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| – | – |
-30,995
| Closed | -$476K |
|
|
TRNX
74
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| – | – |
-469,023
| Closed | -$11.2M |
|
|
AMBI
75
DELISTED
Ambit Biosciences Corp
AMBI
| – | – |
-146,111
| Closed | -$2.25M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q4 2014 Portfolio in Review
As of Q4 2014, Sectoral Asset Management held 76 positions worth $2.23B, down 6.2% from $2.38B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Sectoral Asset Management withdrew a net $391M in Q4 2014, closing 12 positions and reducing 33 holdings. Its most notable exit was AbbVie, an estimated $25.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 89% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in Achillion Pharmaceuticals worth $29.1M.
- Sectoral Asset Management's largest Q4 2014 buy was Achillion Pharmaceuticals: 2,373,810 shares worth $29.1M.
- Sectoral Asset Management added most to Shire pic in Q4 2014, an estimated $34.9M increase.
- Sectoral Asset Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $64.7M.
- Sectoral Asset Management fully exited AbbVie in Q4 2014, selling an estimated $25.7M.
- Sectoral Asset Management's ten largest holdings make up 45% of its $2.23B portfolio in Q4 2014.
- Sectoral Asset Management opened 10 new positions and closed 12 in Q4 2014.
- Sectoral Asset Management's portfolio value fell 6.2% quarter-over-quarter to $2.23B.
Based on Sectoral Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.